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Summary 2-(4-Aminophenyl)benzothiazole (CJM 126) elicits biphasic growth-inhibitory effects against a panel of oestrogen receptor-positive
(ER+) and oestrogen receptor-negative (ER-) human mammary carcinoma cell lines in vitro, yielding IC50 values in the nm range. Substitutions
adjacent to the amino group in the 2-phenyl ring with a halogen atom or methyl group enhance potency in sensitive breast lines (pM IC50
values). Transient biphasic dose responses were induced but rapidly eradicated after specific drug exposure periods. Two human prostate
carcinoma cell lines were refractory to the growth-inhibitory properties of2-(4-aminophenyl)benzothiazoles; IC50values > 30 ,UM were obtained.
Potency and selectivity were confirmed when compounds were examined in the National Cancer Institute's Developmental Therapeutics
screen; the spectrum of activity included specific ovarian, renal, colon as well as breast carcinoma cell lines. Moreover, comparing 6-day and
48-h incubations, the exposure time-dependent nature of the biphasic response was corroborated. Differential perturbation of cell cycle
distribution followed treatment of MCF-7 and MDA 468 cells with substituted 2-(4-aminophenyl)benzothiazoles. In MDA 468 populations only,
accumulation of events in G/M phase was observed. Two MCF-7 cell lines were established with acquired resistance to CJM 126 (IC50 values
> 20gM), which exhibit cross-resistance to substituted benzothiazoles, but equal sensitivity to tamoxifen and doxorubicin. Compared with
standard anti-tumour agents evaluated in the National Cancer Institute in vitro cell panel, benzothiazoles revealed unique profiles of growth
inhibition, suggesting a mode(s) of action shared with no known clinically active class of chemotherapeutic agents.
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We have previously reported on the biological properties of poly-
hydroxylated 2-phenylbenzothiazoles (Stevens et al, 1994), which
were originally designed as potential tyrosine kinase inhibitors
modelled on structural comparisons with the flavone quercetin and
isoflavone genistein (Yates et al, 1991). 2-(4-Aminophenyl)benzoth-
iazole (CJM 126) (Figure 1), prepared as a synthetic intermediate in
this programme, was found to elicit pronounced inhibitory effects
against certain breast cancer cell lines in vitro with an intriguing
biphasic dose-response relationship (Shi et al, 1996). Analogues of
CJM 126 were prepared and structure-activity relationships derived
using oestrogen receptor-positive (ER+) MCF-7 and oestrogen
receptor-negative (ER-) MDA 468 cell lines. Modification of the
heterocyclic nucleus to generate benzoxazole or benzimidazole
congeners ofCJM 126had adyschemotherapeutic effect. Incontrast,
substitution at position 3 in the phenyl ring with a halogen atom or
alkyl group enhanced potency in the breast carcinoma panel and
extended the in vitro spectrum of activity to include certain human
ovarian, lung, renal and colon carcinoma cell lines (Shi et al, 1996).
In vivo evaluation ofselected 2-(4-aminophenyl)benzothiazoles also
demonstrated significant tumour growth inhibition against ER+
(MCF-7 and BO) and ER- (MT-l and MT-3) human mammary
xenografts growing inimmune-deprived mice.
A rewarding feature of this new class of compounds is their
simple structure and ease of synthesis (Stevens et al, 1995; Shi et
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al, 1996). The nature of the substituent introduced adjacent to the
amino group has a profound influence on the physical properties
of these compounds, affecting their aqueous solubility, pKa and
sites of protonation (Wheelhouse et al, 1996). Furthermore, it is
clear that small modifications in structure influence the biological
action of compounds in the series. In this report, we describe the
nature of the biphasic dose response observed in sensitive cell
lines with this novel class ofagent.
MATERIALS AND METHODS
Drugs and media
CJM 126, DF 129, DF 203, DF 209 and DF 229 (Figure 1) were
synthesized according to published methods (Shi et al, 1996) in
our laboratories. Stock solutions of drugs (10 mM) were prepared
in dimethyl sulphoxide (DMSO) and stored, protected from light
at 4°C for 4 weeks. Serial dilutions were prepared in medium
before assay. RPMI 1640 tissue culture medium was obtained
from Gibco (Paisley, UK). Fetal calf serum (FCS) was purchased
from Globepharm (Esher, UK). Phosphate-buffered saline (PBS)
was supplied by Oxoid (Basingstoke, UK). Amersham (Bucks,
UK) supplied [3H]thymidine. All other reagents were purchased
from Sigma (Poole, UK).
In vitro growth-inhibitory assays
All cell lines were routinely maintained in RPMI 1640 medium
containing 2 ,UM L-glutamine and supplemented with 10% FCS,
Part 5 ofthe series 'Antitumour benzothiazoles.' Part 4 refers to Wheelhouse et al,
(1996). This work was supported by the Cancer Research Campaign, UK.
745746 TD Bradshaw etal
R
N -
> /N HNH2
Compound R
CJM 126 H
DF 129
DF 203 CH3
DF 209 Br
DF 229 CI
Figure 1 Structure of 2-(4-aminophenyl)benzothiazole compounds
100 IU ml-' penicillin and 100gg ml-' streptomycin in an
atmosphere of 5% carbon dioxide. Cells were subcultured twice
weekly to maintain logarithmic growth.
For inhibition assays, cells were seeded into 96-well plates at a
density of2.5 x 102 per well and allowed to adhere for 4 h before
drug was introduced. A final drug concentration range between
1 pM and 100gM was achieved (n = 8). Cultures were incubated
for 10 days (MDA 468) or 7 days (all other cell lines). For 72-h
incubation assays, cells were seeded at a density of 5 x 103 per
well. At the time of drug addition, an assay was performed to
obtain mean absorbance at this cell density (n = 72). 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
final concentration 400 jg ml-1) was added to each well. The
following 4-h incubation period allowed metabolism of MTT by
mitochondrial dehydrogenases ofviable cells to form an insoluble
formazan product. Medium was aspirated and formazan solubi-
lized by addition of DMSO (100 jl) and glycine buffer (25 jl).
Absorbance, as a measure of viable cell number, was read at
550 nm on an Anthos Labtec systems plate reader.
Establishment of MCF-7 variant cell lines resistant to
CJM 126
MCF-7 cells were subcultured in RPMI 1640 medium containing
2 jM L-glutamine, 10% FCS, 100 IU ml-' penicillin, 100 jg ml-'
streptomycin and either 1Onm CJM 126 or 1OgM CJM 126.
Medium was replaced twice weekly and, after acquisition of
dividing cultures, cells were subcultured twice weekly to maintain
logarithmic growth.
Measurement of agent cytotoxicity
This was estimated by measuring the leakage of lactate dehydro-
genase (LDH) from cells damaged by toxic insult. Cells were
seeded into 24-well plates in medium supplemented with 1% FCS
at a density of 105, 5 x 104 or 2.5 x 104 per well and allowed 4 h to
attach before drug was administered (final concentration 1 nM-
100 jM, n = 3; control, n = 6). After 24-144 h of exposure,
medium was collected, centrifuged to pellet any debris, then
assayed for LDH activity. Concurrently, cell counts were
performed using a haemocytometer. The oxidation of NADH to
NAD+ by LDH was measured spectrophotometrically by moni-
toring the decrease in absorption at 340 nm over 5 min
(Leathwood and Plummer, 1969) on a Pye Unicam SP8-400
UV/VIS spectrophotometer. Maximal release of LDH, repre-
senting 100% cell death, was determined after lysis of untreated
cells in 1% Triton-X-100. LDH release was measured in untreated
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Figure 2 The activity of (A) CJM 126, (B) and (C) DF 129 against human
mammary carcinoma cell lines. (A) and (B) MCF-7 and MDA 468 cells were
plated at seeding densities of 2.5 x 102 per well and exposed to drugs for 7
and 10 days respectively. (C) Cells, seeded at 5 x 103, were treated for 72 h
with DF 129. Growth performance was assessed by MTT assay. Mean and
standard deviations are given for one representative experiment in which
n = 8. Experiments were performed at least three times
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Table 1 Selective activity of 2-(4-aminophenyl)benzothiazoles against
human-derived cancer cell lines in vitro
IC50 (nm)
CJM 126 DF 129 DF 203 DF 209 DF 229
Breast
MCF-7 0.30 0.019 0.017 0.085 <0.01
MDA 468 1.60 0.07 0.18 <0.01 <0.01
SKBR3 26.00 <0.01 <0.01 <0.01 <0.01
Prostate
DU 145 30 800 60 100 >100 000 40 000 44 800
PC3 43 200 36400 >10 000 70 400 31 800
Colona
HCT-116 <10 <10 <10
HCT-15 10 000 7586 55 957
Renala
TK-10 <10 <10 <10
ACHN 47 863 67 857 68 333
Melanomaa
UAC-257 <10 <10 <10
SK-MEL-28 >100 000 >100000 >100000
Cells were seeded at a density of 2.5 x 102 per well, allowed 4 h to adhere
before being challenged with concentrations of CJM 126, DF 129, DF 203,
DF 209 or DF 229 between 1 pM and 100gM. After a 7-day incubation
(10 day MDA 468) MTT assays were performed. Mean values of
representative experiments are given (n = 8, standard deviations <5%). aCells
were exposed to concentrations of DF 129, DF 209 and DF 229 between 10
nm and 100gM for 6 days before growth and viability were assessed using
the sulphorhodamine B assay.
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cells to obtain a value representing natural cell death. Agent cyto-
toxicity was calculated as the percentage ofTriton-releasable LDH
activity per 105 cells, and cellular viability together with growth
was represented graphically.
NCI cytotoxicity assays
The NCI protocol has been described previously (Boyd, 1989).
Briefly, cell lines were inoculated onto a series of 96-well plates.
Seeding densities varied depending upon growth characteristics.
After a 24-h drug-free incubation, test compounds were added
routinely at five tenfold dilutions starting at maximum 104 M.
After incubation periods of48 h or 6 days, cell growth or viability
was assayed using the sulphorhodamine B procedure (Boyd and
Paull, 1995).
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Figure 3 Effect of DF 203 on MCF-7 viability. Cells were seeded into 24-
well plates at densities of (A) 5 x 104 and (B) 2.5 x 104 per well. After
adherence to plastic (4 h), drug was introduced. LDH leakage from cells
exposed to DF 203 for (A) 96 h and (B) 144 h was measured and cells
counted. Toxicity was calculated as described in Materials and methods. Per
cent growth and viability are expressed. Mean ± standard deviations from two
experiments are shown
COMPARE analysis
COMPARE is the computerized pattern-recognition algorithm
used in evaluation ofdata generated by the NCI screen (Weinstein
et al, 1997). It is a method of determining and expressing the
degree of similarity or lack thereof of mean graph profiles gener-
ated on compounds. The response profile fingerprints of 2-(4-
aminophenyl)benzothiazoles were used as 'seeds' to probe other
mean graph data bases to examine whether any closely matching
profiles exist.
Cell cycle distribution
Cell cycle distribution was analysed in control and treated cell
cultures based on the method described by Nicoletti et al (1991).
Briefly, after treatment, cells were washed twice in ice-cold PBS.
Fluorochrome solution, containing 50 ,ug ml' propidium iodide,
0.1% sodium citrate, 0.1% Triton-X-100 and 0.1 mg ml- ribo-
nuclease A, was added (1 ml I0" cells). Samples were transferred
to polypropylene tubes and kept at 4°C. Linear analysis was
performed on a Becton Dickinson fluorescence-activated cell
sorter (FACS) machine using Lysis II program version 1.1.
Measurement of DNA synthesis
Activity in S-phase of the cell cycle was measured after tritiated
thymidine incorporation. Cells were seeded at densities of 5 x
10"-1.5 x 105 per well in 24-well plates and allowed 4 h to adhere
before addition of drug (final concentration range 1 nM-100 ,UM,
n = 3; control, n = 6). Exposure periods between 24 h and 96 h
preceded introduction of [3H]thymidine into wells (1 gCi ml').
After a 4-h incubation, cells were washed (x 6) in ice-cold PBS
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Figure 4 Effect of DF 129, DF 209 and DF 229 on the growth of the renal
cell line TK10 after (A) 48-h and (B) 6-day exposure
and placed at 4°C for 30 min in acid fixative (50% methanol, 10%
acetic acid). Cells were washed twice more in ice-cold PBS and
solubilized in 2 x 200 Vl of 1% sodium dodecyl sulphate (SDS).
Scintillation fluid (4 ml) was added to each sample, which was
vortexed and then counted on a Tricarb liquid scintillation
analys,er.
RESULTS
In vitro examination of biphasic dose responses
The biphasic dose responses elicited by CJM 126 upon sensitive
MCF-7 (7 days) and MDA 468 (10 days) human breast carcinoma
cell lines are illustrated in Figure 2A. Maximum growth arrest
followed exposure of cells to 100 nm and 300 nM. At concentra-
tions between 3 ,UM and 30,M, healthy proliferating colonies were
observed amidst dying cells. Table 1 shows IC50 values obtained
during the initial growth-inhibitory phase in sensitive cells.
Initial screening by MTT assay after a 7-day (10 days for MDA
468) exposure to DF 129 (Figure 2B), DF 203, DF 209 and DF 229
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Figure 5 (A) Contrasting effects of continued exposure vs brief exposures
of MCF-7 cells to 30 gM CJM 126. Cells were seeded at a density of 2.5 x 102
per well. After 4 h, 30 gM CJM 126 was introduced to wells. Cultures were
washed 72 h, 120 h, 168 h and 240 h after initial treatment and replaced with
either medium alone or medium plus CJM 126. MTT assays monitored
cellular progress. Untreated cultures (controls) were washed and replenished
with medium alone. Growth of these cells was not significantly different from
unwashed samples. Mean ± standard deviations from one experiment are
shown in which n = 8. The experiment was performed three times. (B) Effect
of CJM 126 (10 and 30gM) on MCF-7 proliferation inhibited by 10 nm DF 129.
Cells were seeded at a density of 2.5 x 102 per well, allowed 4 h to attach
before introduction of CJM 126 and/or DF 129. After a 7-day incubation, MTT
assays were performed. Mean ± standard deviations (n = 16) are shown
demonstrated the selectivity and exquisite potency of these
compounds (Table 1). Whereas IC50 values > 30 gM were obtained
in two cell lines originating from tumours ofthe prostate (DU 145
and PC3), pM IC50 values were observed in three sensitive breast
cancer cell lines tested. Increasing compound concentration
resulted in decreasing cell numbers; no viable cells were detected
at concentrations 2 10 nM.
Analysis of the growth-inhibitory activities of DF 129 (Figure
2C), DF 203, DF 209 and DF 229 in MCF-7 and MDA 468 sensi-
tive breast cell lines after a 72-h exposure did however reveal
biphasic dose-response relationships. Dose-dependent decline
in cell numbers accompanied increasing DF 129 concentrations
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Figure 6 Flow cytometric analyses of cell cycle distribution after exposure
to benzothiazoles. Representative DNA histograms of (A) MCF-7 and (C)
MDA 468 control populations in log-phase growth are shown. MCF-7 cells
(B), MDA 468 cells (D) were exposed to DF 129 (30gM) for 72 h before cell
cycle analysis
(3 pM-300 nM). However, between concentrations of 1 JM and
30 JM, increased absorbance, representing rising cell numbers
revealed the second, proliferative stage ofthe dose-response rela-
tionship. Absorbances at the initial seeding density of5 x 103 were
0.2484 and0.649 in MCF-7 and MDA 468 cells respectively. Thus
initialIC50 values <1 nm were estimated forMCF-7 and MDA 468
respectively; in addition, an LC50 value of 7.25 nm was estimated
in MDA 468 cells. Assays to measure tritiated thymidine uptake
(see later), LDH release or simply cell counting exposed biphasic
cytotoxic dose responses 24 h, 48 h and 72 h after initial treatment
with DF 129, DF 209 and DF 229, but persisting up to 120 h after
challenge with DF 203. Figure 3 shows data obtained after LDH
assay of MCF-7 cells exposed to DF 203. After a 96-h exposure,
growth and viability decreased with increasing drug concentra-
tions up to maximum cytotoxicity after 100 nm exposure. Viable,
dividing cell colonies were observed in wells treated with 10 JM
DF 203. However, after 144 h of incubation, the proliferative
potential associated with 10 JM DF 203 was absent and cell
viability was negligible. An LC50 value < 1 nm was obtained.
Initial investigations performed at the NCI after a 48-h drug
exposure revealed powerful growth inhibition of selected human-
derived tumour cell lines (Shi et al, 1996). For example, IC50
values < 10 nm were obtained in the TK1O renal cell line after
treatment with DF 129, DF 209 or DF 229 (Figure 4A). However,
cell line ACHN, also of renal origin, gave IC50 values > 100JM.
Biphasic dose responses were encountered in sensitive breast,
renal, ovarian and colon cell lines. Maximum growth arrest
occurred between concentrations of 10 nM and 1 JIM. Increased
growth potential accompanied exposure to 10 JM and 100 JM.
Subsequent examination of cell growth after 6-day incubations
identified additional sensitive cell lines, for example melanoma,
and confirmed potency, selectivity and the transitory nature ofthe
biphasic dose response (Table 1). Although not fully eradicated,
the biphasic trend of the dose-response curve observed in TK1O
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Figure 7 Disarrangement of DNA distribution after exposure of MDA 468
cells to 30gM DF 129. Mean ± standard deviations of two or three samples
are shown; 10 000 events per sample were examined
cells after a 48-h treatment had significantly diminished with
extended incubations (Figure 4B).
In contrast, continuous exposure ofMCF-7 cells to CJM 126 was
essential to maintain the second, proliferative stage ofthe biphasic
response. Exposure to CJM 126 (24-120 h) followed by drug-free
incubation periods (144-48 h) did not affect the growth-inhibitory
profile at concentrations < 1 gM (data not shown). However, the
'proliferative' phase, between CJM 126 concentrations of3gM and
30gM was notdetected. Figure 5A illustrates thatremoval of30gM
CJM 126 by aspiration ofmedium and drug 72 h, 120 h, 168 h and
240 h after treatment, and subsequent washing ofcells (x 2) before
replenishment with medium alone, appeared to induce immediate
cell death. Aspiration of well contents, subsequent washing and
replenishment with medium and CJM 126 did not affect the
biphasic growth response. The apparent proliferative signal
emanating from the continued presence of 10gM or 30gM CJM
126 was not confined to the rescue of CJM 126-induced growth
arrest. MCF-7 cells, growth inhibited after a 7-day exposure to
1OnM DF 129 recovered their proliferative potential when co-
incubated with 10gM or 30gM CJM 126 (Figure SB).
Cell cycle distribution
FACS analysis was used to examine cell cycle distribution in
cultured cells exposed to 2-(4-aminophenyl)benzothiazoles.
Representative DNA histograms ofMCF-7 and MDA 468 popula-
tions exposed for 72 h to 30gM DF 129 are shown. After imme-
diate treatment, both MCF-7 and MDA 468 cells continued to enter
and progress through S-phase, but ceased S-phase entry after a
96-h exposure to DF 129 (120h, DF 203). Indeed, a small but
highly consistent S-phase peak was obtained in MCF-7 cells
(Figure 6B) accompanied, inconsistently, by a hypodiploid DNA
peak. Strikingly, in MDA 468 cells only, events accumulated and
arrested in G2/M cell cycle phase before population death (Figure
6D). In treated populations of both cell lines, a corresponding
decrease in GI phase was observed. Figure 7 follows MDA 468
populations treated with 30gM DF 129, demonstrating the accumu-
lation of events in S/G/M cell cycle phases accompanied by a
decline inG1 events. CJM 126failed to induce G2/M blockin MDA
468 cells. Activity in S-phase after a 48-h exposure to DF 129 and
CJM 126 (10gM) has been confirmed by measurement of tritiated
thymidine uptake and contrasts with S-phase activity afterexposure
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Table 2 Effect of experimental and therapeutic agents on MCF-7 parent cell
line and CJM 126-resistant variants.
IC50 (nm)
MCF-7 LT 10 nM LT 10 ,M
CJM 126 0.3 28 900 58 900
DF 129 0.019 612.7 92.4
DF 203 0.017 906 628.9
Doxorubicin 4.61 3.21 4.23
Tamoxifen 538 250 530
Mitomycin C 1.14 1.35 2.13
Actinomycin D <0.1 <0.1 <0.1
MTT assays, as a measure of viable cell number, were performed after a 7-
day drug exposure. Mean values of two experiments are shown (n= 8 per
experiment). Standard deviations <10%. 10 AM
229 was observed whereas sensitivity to other chemotherapeutic
agents, including tamoxifen and doxorubicin, was conserved.
E 15 000
CL
0 r_
m 10000
0
o
0
._
,c
£ 5000
._.
0
*CJM 126
E DF 129
Control 1 11M 10 gM
Figure 8 Effect of DF 129 and CJM 126 on the proliferative potential of
MDA 468 cells. Cells were seeded into 24-well plates at densities of (A)
1.0 X 105 and (B) 5 x 1 4 per well and allowed 4 h to attach before
introduction of drug. After (A) 48-h and (B) 96-h exposure, cells were pulsed
with 1 pCi ml-l [3H]thymidine. Mean ± standard deviations are given for three
experiments
ofcells to concentrations ofDF 129 or CJM 126 < JIgM (Figure 8).
After a 96-h exposure, evidence of proliferation remains only in
MDA 468 populations treated with 10 JM CJM 126.
The cell cycle dynamics ofDU 145 prostate cells remained unper-
turbed after exposure to substituted benzothiazoles (not shown).
Resistance studies
Two variant cell lines have been derived from MCF-7 cells
displaying stable resistance to CJM 126. After long-term contin-
ued exposure (> 4 months) to either 10 nM CJM 126 (LT 10 nM) or
10 JIM CJM 126 (LT 10 JM), cells evolved possessing IC50 values
of 28.9 JM and 58.9 JIM, respectively, when rechallenged with
CJM 126 (Table 2). No inhibition of cell growth was observed at
concentrations below 10 JIM. Cells grown in the absence of CJM
126 for 16 passages gave IC50 values > 20 JIM when rechallenged
with this agent. Cross-resistance between CJM 126 and the substi-
tuted benzothiazoles DF 129, DF 203 (Table 2), DF 209 and DF
Compare analysis
Computerized pattern-recognition evaluation of the NCI database
of > 50 000 compounds (Boyd and Paull, 1995) demonstrated that
2-(4-aminophenyl)benzothiazoles substituted in position 3 of the
phenyl ring with a halogen atom or a methyl moiety were
COMPARE negative with all classes of clinically active thera-
peutic agent. DF 203, DF 209 and DF 229 were the only agents
presenting Pearson correlation coefficients >0.7 with DF 129 as
seed compound.
DISCUSSION
Novel compounds have been identified that possess extremely
powerful and highly selective anti-tumour activity in vitro. The
growth-inhibitory profiles induced in sensitive cell lines exposed
to 2-(4-aminophenyl)benzothiazoles did not however present a
classical progressive dose-response profile. At concentrations
examined below 1 gM, dose-dependent decline in cell viability
occurs. Yet at concentrations beyond 1 gM, cells appear to be
subject to bivalent regulation: healthy proliferating colonies
emerged amid dying cells. Furthermore, such dual control of
cellular behaviour is strictly time dependent in the presence of
substituted benzothiazoles (Figure 2B and C, 3 and 8).
The abrupt cessation of proliferation in MCF-7 and MDA 468
cells between concentrations of 1 JM and 100 JIM beyond a 72-h
exposure to DF 129, DF 209 or DF 229 or a 120-h exposure to DF
203 may be a consequence of delayed reproductive or mitotic cell
death that occurs after treatment of cells with drug or radiation,
inducing irreparable damage but allowing cells to complete at least
one cell cycle division (Darzynkiewicz et al, 1994). Pulsing MCF-7
and MDA 468 populations with tritiated thymidine and cell cycle
analyses confirmed continued S-phase activity afterinitial treatment
with concentrations of DF 129 2 10 gM (Figures 6 and 8). MCF-7
cells during this time presented an S-phase peak. Cell cycle analysis
also revealed a corresponding loss of events fromG, (Figure 7). It
appears that sensitive cells exposed to high concentrations of drug
remain committed to continue to S-phase and any damage caused is
not recognized by the GI checkpoint. MDA 468 cells, having
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completed S-phase, become blocked in G2/M. However, cdc2 kinase
and cdc25 phosphatase, regulators of the G2/M transition, were
uninhibited by DF 129 or DF 203 (IC50> 50gm; Dr H Hendricks,
personal communication). Spontaneous cell death may be the
inevitable result of failure in mitosis. Indeed, if cells are blocked in
S, G2 orM forany length oftime they die (Ruddon, 1987; Hotz et al,
1992). Pagliacci et al (1994) observed a persistent G2/M arrest in
MCF-7 cells treated with concentrations of genistein 2 50gM (IC50
40gM). However, at DF 129 concentrations < 1 gM, S-phase activity
became immediately depleted (Figure 8). Lower concentrations of
benzothiazoles may impose a block on exit from G . Pickard et al
(1995) demonstrated a predominantly G, arrest at low doses of 5-
fluorouracil in human embryonic fibroblasts, but, after treatment
with higher concentrations, G,/M arrest was recorded.
Intriguingly, concentrations of CJM 126 (3 gM-30gM) within
the proliferative stage of the dose response sustained proliferating
colonies at all time points examined (up to 11 days). Moreover, the
presence of CJM 126 appears to be an absolute requirement to
support the second 'proliferative' phase. Loss of viability after
removal ofCJM 126 and rescue ofDF 129-induced growth inhibi-
tion by 10gM and 30gM CJM 126 (Figure 5A and B) corroborate
this view. Chemicals, including the metabolic product catechol
oestrogen, have been reported to induce cell death and subsequent
compensatory cell proliferation (Yang et al, 1995).
In vitro anti-tumour activity was highly selective (Table 1).
Moreover, data generated at the NCI revealed highly consistent
specific inhibition of cell lines from tumours of the same tissue
origin, for example renal, colon and melanoma (Table 1).
Preliminary evidence has emerged to suggest that anti-tumour
activity and selectivity observed within the ovarian cell panel in
vitro predict drug performance in vivo (manuscript in preparation).
Mechanisms underlying such stark selectivity are not yet under-
stood. A number of potential biochemical targets for these novel
benzothiazoles have been examined (details not shown). No inter-
action with oestrogen receptors or EGF receptors was found. No
effect upon the activity of tyrosine kinase, protein kinase C,
aromatase, lyase, topoisomerase II or telomerase was detected.
Microtubule assembly was not inhibited.
Agent biotransformation at selective tissue sites may be an
important determinant of target organ specificity. Catalytically
active N-acetyltransferase 1 has recently been demonstrated in
human mammary gland ductular epithelial cells (Sadrieh et al,
1996). Indeed, rapid uptake and efficient acetylation of CJM 126
by sensitive breast cell lines has been recorded (manuscript in
preparation) and contrasted with the negligible uptake and acetyla-
tion by unresponsive cell lines of prostate origin. Interestingly, N-
(4-aminobenzoyl)-2-aminoaniline, an aromatic amine of related
structure, which is rapidly N-acetylated by microsomal liver
enzymes, has proved to be a highly effective and specific inhibitor
of colorectal carcinoma; however the definitive mechanism of
action remains to be elucidated (Seelig and Berger, 1996).
Two cell lines displaying resistance to CJM 126 have been
derived after long-term exposure to this agent: LT 10 nm popula-
tions were cultured in the presence of an inhibitory concentration
(10 nM) of CJM 126, whereas LT 10gM cultures were continu-
ously treated with 1O,M CJM 126, a concentration within the
second phase of the biphasic response, which appeared to emit
opposing signals. Mechanism(s) of resistance operating within LT
1O nm and LT 1OgM cell lines appear to be unrelated to the
multidrug-resistant phenotype; sensitivity to chemotherapeutic
agents, such as doxorubicin, was maintained (Table 2).
COMPARE analyses revealing high Pearson correlation coeffi-
cients between DF 129, DF 203, DF 209 and DF 229 infer novel,
but shared, biochemical mechanisms ofaction. In a recent publica-
tion, Akama et al (1996) reported the selective antiproliferative
activity of 5-amino-2-(4-aminophenyl)-4H-1-benzopyran-4-one
against MCF-7 cells. Intriguingly, the mechanism of action ofthis
novel aminoflavone derivative, again not structurally dissimilar to
the benzothiazoles reported in this paper, is not understood.
Finally, the selectivity and potency afforded by compounds
within the benzothiazole family suggest that one or more of these
agents may provide promising candidates for further preclinical
evaluation.
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